The expression of HLA-G by tumour cells is an established mechanism to escape recognition and immune mediated destruction, allowing tumour survival, growth and metastasis. However, the prognostic value of soluble HLA-G (sHLA-G) remains unknown. Mucinous carcinoma (MC) is a distinct form of colorectal cancer (CRC) found in 10 to 15% of patients, which has long been associated with poor response to treatment. To investigate the prognostic value of plasma sHLA-G levels in CRC patients, preoperative plasma sHLA-G levels were determined by ELISA in CRC patients (n 5 133). In addition, the local expression of HLA-G in tumour biopsies was assessed using tissue microarray analysis (n 5 255). Within the high 33rd percentile of sHLA-G levels (265-890 U/mL; n 5 44) we observed higher frequency of MC patients (p 5 0.012; Chi-square), and higher sHLA-G levels in patients with vascular invasion (p 5 0.035; two-tailed t-test). Moreover, MC patients had significantly higher sHLA-G levels compared to those with adenocarcinoma not otherwise specified (p 5 0.036; two-tailed t-test). Surprisingly, while stage II patients showed negative correlation between sHLA-G levels and liver metastasis free survival (LMFS) (p 5 0.041; R 5 20.321), in stage III patients high sHLA-G levels were associated with significantly longer LMFS (p 5 0.002), and sHLA-G levels displayed positive correlation with LMFS (p 5 0.006; R 5 0.409). High HLA-G expression in tumours was associated with poor cancer specific overall survival in stage II to III (p 5 0.01), and with shorter LMFS in stage II patients (p 5 0.004). Our findings reveal that sHLA-G levels are associated with distinct progression patterns in consecutive disease stages, indicating a potential value as surrogate marker in the differential prognosis of CRC.
Colorectal cancer (CRC) is one of the most common malignancies in the western world, with Australia and New Zealand showing the highest CRC incidence per capita. 1 The prevalence of CRC in developing countries has also increased substantially, 2 and early-onset CRC is on the rise. 3 Early diagnosis, improved surgical techniques and new treatment protocols have significantly improved patient survival in the last decades. However, CRC remains a major cause of cancer-related death worldwide mainly due to spread of cancer cells to distant organs. Therefore, interventions to further reduce CRC burden and mortality based on prognostic biomarkers to inform selection of therapeutic protocols are warranted. CRC is preventable and potentially curable when tumour and high-risk adenoma are detected and removed at an early stage. Five-year survival rates range from 90% for patients with localized disease down to 70% and 13% for regional and distant metastasis respectively (American Cancer Society. Colorectal Cancer Facts and Figures 2014-2016) . Staging, which is currently the most important prognostic indicator for CRC, involves margin clearance, depth of tumour penetration through the bowel wall and the degree of lymph node involvement. Recovery and evaluation of lymph nodes in the resected specimen is, however, influenced by method and quality of the surgical resection, quality of pathologic evaluation, tumour-and patient-related factors. 4, 5 Disease management in CRC is currently guided mainly by staging after tumour resection, and adjuvant chemotherapy is normally administered to CRC patients with lymph node invasion (stage III). The benefit of adjuvant chemotherapy in stage II CRC patients remains controversial. 6, 7 Therefore, patient stratification based on both conventional staging and molecular profiling of prognostic biomarkers is required to select those who will benefit from adjuvant chemotherapy and avoid exposure to chemotherapy in patients who would have least or no benefit. Moreover, the development of novel immunotherapies for CRC requires identification and validation of novel biomarkers and clinical measurement assays for stratification of patients according to the immune escape mechanisms manifested by their tumours. 8 HLA-G is a nonclassical major histocompatibility complex (MHC) class Ib molecule 9 with low polymorphism, expressed in specific cell types and tissues. It was first identified in the trophoblast from early gestation placentas, where it revokes maternal natural killer (NK) cell activity against foetal tissue and establishes immune tolerance at the maternal-foetal interface. 9 Paul et al. (1998) discovered the expression of this molecule in melanoma cells. 10 Since then HLA-G expression has been reported in various cancers including melanoma; 10 ovarian carcinoma; 11 myeloma; 12 myeloid leukemia; 13 glioblastoma; 14 and breast cancer. 15 Ibrahim et al. (2004) reported that HLA-G expression was associated with malignant transformation and that up-regulation of HLA-G expression in melanocytic cells was a predictor of malignancy. 16 In chronic lymphocytic leukaemia, HLA-G expression on the surface of tumour cells was shown to have prognostic significance. 17 The expression of HLA-G is well established as a mechanism utilised by tumour cells to escape host immune-surveillance. Accordingly, it has been shown that HLA-G expression allows tumour cells to escape cytotoxic T lymphocyte (CTL) mediated recognition and destruction, to survive and to grow.
18
HLA-G consists of seven isoforms. HLA-G1 to HLA-G4 isoforms are membrane-bound whereas HLA-G5 to HLA-G7 are soluble isoforms. 19 Soluble HLA-G (sHLA-G) is derived from the secretion of soluble isoforms as well as from the shedding of proteolytically cleaved membrane bound isoforms. 9 Soluble HLA-G is mainly produced and secreted by immune cells including monocytes/macrophages and myeloid/plasmacytoid dendritic cells. 9 High sHLA-G containing sera were shown to inhibit NK cell and CTL-mediated neuroblastoma cell lysis. 14 To date, few studies investigated the prognostic value of HLA-G expression in CRC. Ye et al.
suggested that local HLA-G expression was an independent prognostic factor and that HLA-G might serve as an independent prognostic marker for CRC progression. 20 Hansel et al. reported HLA-G expression in normal epithelial tissue, especially in cells adjacent to adenoma and carcinoma. They also observed higher HLA-G expression in tubulovillous adenoma compared to carcinoma and liver metastases.
21
Circulating sHLA-G has been demonstrated in healthy subjects as well as in cancer patients, however not much is known about its prognostic value. Zhou et al. 22 reported that the concentration of sHLA-G in serum of healthy controls was significantly lower than in cancer patients, however, the concentration of sHLA-G in CRC patients was not significantly different compared to patients who had hyperplastic polyp, inflammatory bowel disease or adenoma. 22 Cao et al.
23
found that sHLA-G concentration in plasma of early-stage CRC patients was significantly higher than in healthy controls. They therefore suggested that plasma sHLA-G could serve to distinguish between patients with colorectal tumours and those with benign polyps. 23 The main aim of the present study was to determine the prognostic value of circulating sHLA-G in different CRC stages. To this end, we investigated the correlation between the preoperative level of sHLA-G in plasma and validated clinical-pathological parameters of CRC progression. The majority of colorectal cancer (CRC)-related deaths are attributable to liver metastasis. However, there is no prognostic biomarker that predicts metastatic risk and allows informed selection of preventive treatment. The translational challenge, therefore, is to develop surrogate markers of metastatic progression. HLA-G expression by tumours is an established immune escape mechanism, and so the present study set to determine the prognostic value of circulating soluble HLA-G in different CRC stages. The findings reveal that sHLAG levels are associated with distinct progression patterns in consecutive disease stages, indicating its potential value as a surrogate marker in the differential prognosis of CRC.
Materials and Methods

056/AM03) and the TQEH/LMH/MH Human Research Ethics
Committee (HREC/14/TQEHLMH/164).
Measurement of soluble HLA-G in plasma
Soluble HLA-G was quantified using a commercially available ELISA kit (Exbio, Prague, Czech Republic) according to the manufacturer's instructions. Briefly, calibrators and plasma samples were incubated in microtitration wells precoated with mouse anti-HLA-G monoclonal antibody (MEMG/9), which recognizes the most abundant soluble isoforms (membrane shedded sHLA-G1 and intron4-containing secreted sHLA-G5). After 60-min incubation and washing, monoclonal anti-human beta2-microglobulin antibody labeled with horseradish peroxidase (HRP) was added to the wells and incubated for 60 min, which recognized the immobilized antibody-sHLA-G complex. Following another washing step, the substrate (H 2 O 2 with tetramethylbenzidine) solution was added to react with the remaining HRP-conjugated antibody. After the addition of acidic stop solution, the absorbance of resulting yellow product was then measured at 450 nm using a microplate reader (iMARK TM Microplate Reader, Bio-Rad). According to absorbance values proportional to sHLA-G concentrations of calibrators, a calibration curve was constructed, and the sHLA-G concentrations of plasma samples were determined. Plasma samples were analysed in batches at the same time.
Tissue microarray analysis
Five TMA slides with 55 tissue cores per slide (275 cores in total) were constructed. Each patient was represented as single tissue core in the TMAs, allowing analysis of 255 primary CRC cases (20 tissue cores could not be analysed due to tissue damage or loss during TMA processing). Formalin-fixed, paraffin-embedded tissue blocks of CRC tumour biopsies were obtained from the Wakefield hospital tumour archive. Prior to constructing each TMA, a 4 lm section was sliced from each tumour block for a routine hematoxylin and eosin stain and histologic confirmation by a pathologist at the Department of Pathology, University of Otago, Wellington, New Zealand. Areas of sampling defined and marked on the microscope slide were used as a reference to guide the location of tissue cores for punching. TMAs were manually constructed using a 2 mm disposable biopsy punch (Kai medical, Kai Europe GmbH Germany) on Quick-Ray TM paraffin recipient block 2 mm 3 60 wells (IHC World, MD). A tissue core with a diameter of 2 mm was punched from the donor tissue block under the guidance of reference slides and transferred to a recipient ready-made paraffin block.
Immunohistochemistry
One 4-lm thick tissue section was cut from each TMA block. All subsequent procedures were carried out at room temperature unless otherwise stated. Tissue sections were rehydrated. Antigen retrieval was performed by submerging the slides in sodium citrate buffer (10 mM sodium citrate buffer (pH 6), 0.05% Tween20) in microwave for 15 min. After cooling, sections were incubated in 3% H 2 O 2 in PBS-T for 10 min to block endogenous peroxidase. Sections were then sequentially blocked in 2.5% normal horse serum in PBS-T for 30 min. Tissues were then incubated in a humidified chamber with the mouse monoclonal anti-HLA-G (4H84) antibody (1:50, sc-21799; Santa Cruz Biotechnology) diluted in 1.25% normal house serum in PBS-T for 1 h. Specific bindings were detected using R.T.U VectastainV R Universal Quick Kit (PK-7800, Vector Laboratories Inc., CA) and DAB substrate (SK-4100, Vector Laboratories Inc., CA). A pathologist and a medical scientist, both blinded to patient identity and clinical parameters, independently scored HLA-G expression in the tumour cells and re-evaluated specific sections together to conclude the final score. The intensity of HLA-G in tumour cells was scored as 0 for negative staining, 1 for moderate or 2 for strong staining (Fig. 3 ).
Statistical analysis
The statistical analysis was performed using SPSS 17.0 software (SPSS, Chicago, IL) and GraphPad-Prism version 6 software (Graph software, San Diego, CA). A comparison between the two groups was performed using the nonparametric Mann-Whitney test. Multiple comparisons among three groups were analysed using the Kruskal-Wallis test. Correlations between HLA-G expression and clinical parameters were calculated with Pearson's v 2 test. Correlations between sHLA-G levels and the pathological or clinical parameters were evaluated using Pearson's correlation coefficient. Difference of sHLA-G in plasma between groups was analysed with Mann-Whitney U test or the nonparametric Spearman's correlation test. Survival probabilities were calculated using the Kaplan-Meier survival analysis. Correlation between survival time and multiple clinical or pathological variables was assessed by multivariate analysis using the Cox regression analysis. All of the statistical analyses were twotailed and a p < 0.05 was considered to be statistically significant.
Results
Higher levels of soluble HLA-G in mucinous carcinoma patients
To determine the prognostic value of circulating soluble sHLA-G protein we analysed plasma samples from a cohort of CRC patients. First, we examined the correlation between peripheral blood sHLA-G and clinical-pathological parameters. Indeed, analysis of plasma sHLA-G levels of the whole CRC patient cohort (n 5 133) reveals higher levels of sHLA-G in mucinous carcinoma (MC) patients (Fig. 1a) . Thus, MC patients (n 5 16; average sHLA-G level 362 unit/mL) displayed significantly higher sHLA-G levels (p 5 0.036; twotailed t-test) compared with patients with adenocarcinoma not otherwise specified (AC; n 5 117; 224 unit/mL). Next, we performed multiple regression analysis of peripheral sHLA-G levels against CRC clinical parameters in the three
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33rd percentiles representing negative/low (n 5 44; 0-8 unit/ mL), moderate (n 5 45; 80-261 unit/mL), and high (n 5 44; 265-890 unit/mL) sHLA-G expression levels. Table 1 summarises the data for the 33rd percentile of patients with high sHLA-G plasma concentration. Interestingly, within the high 33rd percentile, patients with vascular invasion had significantly higher (p 5 0.035; two-tailed t-test) plasma sHLA-G levels (701.1 6 218.8 unit/mL) compared to patients without vascular invasion (516.5 6 211 unit/mL; Fig. 1b ). In addition, higher plasma sHLA-G levels showed a general trend towards positive correlation with several clinical parameters indicating worse prognosis, including TMN disease stage and distant metastasis. Notably, the concentration of sHLA-G was higher in patients in stage IV metastatic CRC patients compared to stages I, II and III, however the difference was not statistically significant (p 5 0.094; Table 1 ).
By grouping CRC patients in 33rd percentiles according to their low, medium or high plasma sHLA-G level, we also evaluated the frequency of patients with high sHLA-G level in patient subsets displaying prognostic clinical parameters (Table 2) . Notably, as shown in Table 2 , v 2 analysis found significant differences in the frequency of high sHLA-G plasma levels in patients with vascular invasion (p 5 0.037) and in MC patients (p 5 0.012).
Prognostic patterns and sHLA-G levels in different TNM disease stages
The prognostic value of plasma sHLA-G depends to a large extent on the effectiveness of this marker in predicting the risk of liver metastasis in stage II and III CRC patients. To determine this capacity, we analysed the correlation between sHLA-G levels and LMFS in sequential disease stages. In stage II patients (n 5 41), analysis of the continuous data found negative correlation between sHLA-G levels and LMFS (R 5 0.321; Spearman's correlation coefficient). Indeed as shown in Figure 2a , higher sHLA-G concentration in plasma correlated with shorter LMFS. Next, we analysed the correlation between sHLA-G plasma levels and LMFS in TMN stage III patients. Figure 2b shows the correlation between sHLA-G levels and LMFS in stage III patients. Surprisingly, higher sHLA-G levels in stage III patients showed significant positive correlation with (32) 1 Percentage of the column. 2 Percentage of the row. 3 Total number of sample was 128 due to missing data.
longer LMFS (n 5 44; R 5 0.409; Spearman's correlation coefficient). Moreover, as shown in Figure 2c , Kaplan-Meier analysis revealed that stage III patients in the high 33rd percentile of sHLA-G level (n 5 13; 265-890 unit/mL) displayed significantly longer LMFS compared to both stage III patients with intermediate sHLA-G levels (n 5 18; 80-261 unit/mL; p 5 0.027), and patients with low sHLA-G levels (n 5 13; 0-8 unit/mL; p 5 0.002). Remarkably, as shown in Figure 2c , only 1 of 13 (7.7%) stage III patients with high sHLA-G progressed to liver metastasis within 80 months follow up after tumour resection, compared to 8 of 18 (44.4%) patients with intermediate sHLA-G levels and 8 of 13 (61.5%) of the stage III patients with low/negative plasma sHLA-G levels. These results indicate that the level of sHLA-G in peripheral blood can represent conflicting disease progression patterns in consecutive disease stages.
Strong local HLA-G expression in tumour cells is associated with worse prognosis
We determined the expression level of HLA-G protein in tumour biopsies by blind scoring of 255 CRC patients and 10 normal epithelial colon tissue sections, using TMA analysis. This analysis confirmed that HLA-G shows diffused cytoplasmic and cell surface expression specifically in tumour cells. While 37 patients (14%) showed no HLA-G expression (score 0; Fig. 3a ), HLA-G expression was found in 218 (86%) patients, with 206 patients (81%) scored as positive (score 1;
Figs. 3b and 3c) and 12 patients (5%) scored as strong expression intensity (score 2; Fig. 3d ). This analysis confirmed that normal colonic epithelial cells do not express HLA-G (Figs. 3eh) .
We performed statistical analysis of the correlation between local HLA-G expression levels and various clinical parameters. Notably, cancer-specific overall survival of CRC patients showed statistically significant association with the level of local HLA-G expression by tumour cells. Patients with strong HLA-G expression showed significantly shorter cancer-specific overall survival compared to patients with moderate HLA-G expression ( Fig. 4a; p 5 0.04) . Accordingly, patients with strong HLA-G expression showed a significantly shorter LMFS compared to the patients population with moderate HLA-G expression (p 5 0.039; Fig. 4b ). In our CRC patient cohort, Kaplan-Meier survival analysis showed that the cancer specific overall survival and LMFS curves of patients whose tumours had negative or moderate HLA-G expression were similar and overlapping, suggesting that moderate local HLA-G expression is not associated with a survival disadvantage (Fig. 4) .
Next, we analysed the prognostic value of high local HLA-G expression in different CRC disease stages. Indeed, high HLA-G expression in tumour cells of stage II patients was associated with significantly shorter LMFS ( Fig. 2d ; p 5 0.004), whereas in the combined population of stage II-III CRC patients, high local HLA-G correlated with significantly shorter cancer specific overall survival ( Fig. 2c; p 5 0.01) .
In our patient cohort the local expression of HLA-G in tumour tissue did not significantly correlate with recorded clinical-pathological parameters including age, tumour site, type of cancer, histological grade, vascular invasion, perineural invasion, TNM stage, lymph node involvement and depth of tumour cell spread. However, v 2 analysis found a statistically significant correlation between the expression intensity of HLA-G and gender (p 5 0.02). Thus, out of 142 male subjects (56%) and 112 females (44%), respectively 3 (2% of males) and 9 (8% of females) had high local HLA-G expression. Notably, 9 (75%) of the 12 CRC patients with high HLA-G expression in tumour cells were females (Table  S1 in Supporting Information). To assess the prognostic value of local HLA-G expression, we performed a multiple regression analysis (Cox analysis). This analysis found that in our patient cohort, local HLA-G expression was not an independent predictor of cancer specific overall survival (p 5 0.301). Cox regression analysis confirmed that the independent factors associated with cancer specific overall survival include staging (p 5 0.001) Lymph node invasion (p 5 0.006) and perineural invasion (p 5 0.0001; Table S2 in Supporting Information).
Discussion
The main aim of this study was to determine the prognostic value of sHLA-G as surrogate marker of disease progression in CRC patients, by analysis of the correlation between preoperative plasma sHLA-G concentration and clinicalpathological parameters associated with disease progression. Our findings represent, to the best of our knowledge, the first demonstration that: (a) circulating sHLA-G levels are associated with different prognostic patterns in specific CRC disease stages; (b) significantly higher circulating sHLA-G levels are observed in patients with MC, and (c) CRC patients with vascular invasion in the high sHLA-G 33rd percentile have significantly higher sHLA-G levels. These results highlight sHLA-G as differential prognostic marker in CRC patients and suggest that sHLA-G secretion by different cell types is associated with specific progression patterns in consecutive CRC stages. HLA-G was shown to have restricted expression patterns in specific tissues and to exert multiple immunoregulatory functions. 24, 25 It was suggested that HLA-G expression in tumour cells is one of the mechanisms used by the tumour cells to escape immune mediated destruction. 26 As HLA-G binds immunoglobulin-like inhibitory receptors that are expressed by immunocompetent cells such as NK cells, it has been hypothesised that up-regulation of HLA-G expression is used by cancer cells to avoid the NK cell-mediated antitumor immune response, therefore allowing cancer cells to invade into and proliferate in distant organs. 27 On the other hand, sHLA-G was shown to inhibit the in vitro proliferation of neoplastic B cells through immunoglobulin-like transcripts (ILT2). 28 Aberrant expression of sHLA-G has been proposed as a possible prognostic marker and potential target for cancer therapy. However, the mechanisms underlying the differential expression patterns of sHLA-G within a tumour type and among different tumours remain unclear. 9 While the association between HLA-G expression in tumour cells and poor prognosis is well established, both the functional role and the clinical relevance of sHLA-G remain under extensive investigation in various types of cancer. Indeed, it was previously shown that HLA-G is a soluble moiety detectable in body fluids, and that circulating HLA- G1 and HLA-G5 proteins are generated by shedding of the membrane bound isoform and by secretion of a soluble isoform, respectively. 9, 19 It has been suggested that sHLA-G plays a role in the control of chemotaxis of immune effector cells, 29 however, the function of sHLA-G in health and disease remains to be elucidated. Peripheral blood levels of sHLA-G are increased in a number of pathological conditions including various types of cancer, and in some of these conditions, sHLA-G has been shown to be associated with the clinical course of the disease. 30 In other types of cancer, lack of correlation between the levels of HLA-G detected in the tissue and blood of the same patients was previously reported. 31, 32 Higher plasma levels of sHLA-G have been reported in patients with cancer and viral infections compared to healthy subjects, either due to direct release of sHLA-G by tumour cells or virus-infected cells, or due to induction of sHLA-G release by other cell populations such as activated monocytes and dendritic cells. 9 These observations suggest that sHLA-G is secreted by activated immune cells and indicates an ongoing immune response against tumour cells or virus-infected cells. Accordingly, despite the higher levels of sHLA-G in cancer patients compared to healthy controls, the presence of sHLA-G in the circulation is not restricted to cancer patients and is not directly dependent on or correlated with HLA-G expression in tumour cells. 32 Indeed, previous studies showed that peripheral blood monocytes are the predominant cells secreting HLA-G5. 33 In this study, the relatively large number of CRC patients included in our evaluation (n 5 133) allowed for investigation of the prognostic value of plasma sHLA-G. Several clinical studies found no correlation between sHLA-G concentration in plasma/serum and clinical parameters including overall survival and disease free survival in cervical cancer, 34 esophageal squamous cell carcinoma 35 and melanoma patients. 33 On the other hand, in non-small-cell lung cancer patients with squamous cell carcinoma it was shown that high levels of sHLA-G is significantly associated with shorter overall survival. 36 Cao et al. reported that sHLA-G plasma levels are significantly elevated in patients with different types of solid tumours compared to healthy controls. 23 In our CRC patient cohort we observed significantly higher sHLA-G levels in MC patients and in patients with vascular invasion. Interestingly, an association of mucinous carcinomas with HLA-E/b2 microglobulin overexpression in tumour cells, as well as with recruitment of inhibitory immune cells and tumour progression in CRC patients was previously reported. 37 The association of higher sHLA-G levels with mucinous carcinoma and vascular invasion can be related to sHLA-G secretion by either pathogenic pre-metastatic tumour cells or activated inhibitory immune cells recruited to the tumour microenvironment. An open question remains whether both regulatory and effector immune cells secrete sHLA-G upon activation, which might explain the discordance we observed in consecutive CRC stages.
Our findings are in-line with the previously described mechanistic link among the HLA-G receptor killer-cell Iglike receptor (KIR2DL4; CD158d) expression in immune cells, the expression of HLA-G in tumour cells, and invasion/ metastasis in breast cancer patients. 38 Additional mechanistic support to the immunosuppressive function of sHLA-G is provided by earlier literature reporting that sHLA-G induces apoptosis in T and NK CD81 cells, inhibits cytotoxic T-cell activity and that HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD41 T cells. 39, 40 In CRC patients, Zhu et al. 41 reported that median value of sHLA-G concentration in serum was significantly higher than in healthy controls, hyperplastic polyp, inflammatory bowel disease and patients with adenoma. They also suggested that patients with well-differentiated and moderately differentiated tumours had higher sHLA-G than poorly differentiated tumours. 22, 41 Our analysis of the correlation between sHLA-G plasma levels and LMFS in stage II and stage III CRC patients revealed differential correlation in these consecutive TNM stages. As stage III patients have had chemotherapy prior to surgery and sample collection, another possibility is that higher plasma sHLA-G levels result, at least in part, from the damage inflicted to tumour cells, and therefore, sHLA-G is a marker of tumour chemo-responsiveness. Notably, in high-grade ovarian carcinomas, HLA-G (but not sHLA-G) expression was associated with longer progressionfree survival and response to chemotherapy. 32 To address this hypothesis, future research could compare prospective sHLA-G levels in patients who survived for 5 years after chemotherapy with those who did not. Furthermore, the fact that sHLA-G is noted in patients with vascular invasion brings up the question whether it could represent a predictive marker of response to Avastin, which targets vascular proliferation. It would therefore be of interest to correlate sHLA-G levels with the response of Avastin in mCRC patients.
In conclusion, it is well established that HLA-G modulates antitumor immune responses by interacting with specific immunoglobulin-like inhibitory (ILT) receptors expressed by various immune cell subsets. The restricted distribution of HLA-G, slow turnover and its immunosuppressive functions have made HLA-G a promising candidate biomarker and potential therapeutic target. Therefore, the specific mechanisms associated with sHLA-G release by activated regulatory/effector immune cells and intact/injured/dead tumour cells and the value of sHLA-G as prognostic and predictive biomarker deserve extensive examination. Our findings indicate that sHLA-G plays a complex role in the pathophysiology of CRC, possibly due to its secretion by both tumour cells and peripheral blood monocytes. Our results suggest that plasma sHLA-G differential levels could be a useful prognostic marker, and predictive biomarker of response to treatment in progressive CRC stages. Clinically applicable biomarkers of CRC prognosis represent an unmet medical need. Potentially, the combination of sHLA-G with additional systemic immunecheckpoint biomarkers will result in a panel of surrogate molecular markers with sufficient specificity and sensitivity to predict the risk of metastatic progression and the response to certain treatment regimens in sequential CRC disease stages.
